Ọgwụ mgbochi akpa ume nke Akeso nke a na-akpọ PD-1/CTLA-4 Bispecific Cadonilimab ka akwadoro maka ọgwụgwọ mbụ nke ọrịa kansa cervical n'ime ndị niile bi na mba ahụ—ihe ngosi nke atọ akwadoro maka Cadonilimab

Na Juun 04, 2025, Akeso kwupụtara na National Medical Products Administration (NMPA) akwadola ọgwụ mgbochi PD-1/CTLA-4 nke ụlọ ọrụ ahụ, cadonilimab, maka ọgwụgwọ mbụ nke kansa cervical na-adịgide adịgide, na-emegharị ugboro ugboro, ma ọ bụ metastatic, yana chemotherapy dabere na platinum, yana ma ọ bụ na-enweghị bevacizumab. Nkwado NMPA bụ ihe ngosi nke atọ akwadoro maka cadonilimab.

Nkwenye maka ojiji cadonilimab yana chemotherapy (ma ọ bụ na-enweghị bevacizumab) na kansa akpa nwa nke mbụ dabere na data ahụike sitere na ọmụmụ Phase III COMPASION-16 (AK104-303).

N'ime nnwale nke usoro nke atọ a nke a na-achịkwaghị achịkwa, nke nwere ihu abụọ, nke nwere ọtụtụ ebe, nke a na-achịkwa placebo, e kenyere ụmụ nwanyị dị afọ 18-75 n'ofe ebe ahụike 59 na China nwere kansa cervical na-adịgide adịgide, nke na-emegharị ugboro ugboro, ma ọ bụ nke metastatic na-enweghị usoro (1:1) ịnara cadonilimab (10 mg/kg) ma ọ bụ placebo tinyere chemotherapy dabere na platinum yana ma ọ bụ na-enweghị bevacizumab kwa izu atọ maka okirikiri isii, wee soro ọgwụgwọ mmezi kwa izu atọ ruo afọ 2. Emere usoro nhazi site na sistemụ nzaghachi weebụ mmekọrịta. Ihe ndị na-akpata nhazi bụ iji bevacizumab (ee ma ọ bụ mba) na chemotherapy chemotherapy gara aga (ee ma ọ bụ mba). Nsonaazụ abụọ bụ ndụ na-enweghị ọganihu dịka nyocha nke etiti nọọrọ onwe ya na ndụ zuru oke na nhazi nyocha zuru oke.

Na COMPASION-16, usoro ọgwụgwọ cadonilimab gosiri uru dị ịrịba ama n'ọrụ ya n'ahụ ndị ọrịa nwere etuto ahụ nwere ngosipụta PD-L1 na-adịghị mma (CPS <1), nke gụnyere 27.9% nke ndị mmadụ nọ na otu ọgwụgwọ ahụ, ma e jiri ya tụnyere 24.2% na otu njikwa ahụ. Ọmụmụ ihe ahụ zutere ma ndụ na-enweghị ọganihu (PFS) na njedebe ndụ zuru oke (OS), na-egosi mmụba dị ukwuu na njedebe abụọ ahụ maka ndị ọrịa ejiri usoro cadonilimab gwọọ ma e jiri ya tụnyere ọgwụgwọ ọkọlọtọ na ntọala mbụ maka kansa cervical.

Nnyocha nke otu obere sitere na nnyocha COMPASION-16 gosiri na ma ndị nwere PD-L1-positive na PD-L1-negative, n'agbanyeghị na ha gụnyere bevacizumab, ritere uru na ọgwụgwọ ahụ. E gosipụtara nsonaazụ nke nnwale COMPASION-16 dị ka Late-Breaking Abstract (LBA) na Mgbakọ Mba Nile nke 2024 nke International Gynecologic Cancer Society (IGCS), e mesịa bipụta ya na The Lancet ma mesịa kọọ ya ọzọ na Nature Reviews Clinical Oncology.

Nkọwa

Mgbakwunye nke cadonilimab na ọgwụgwọ chemotherapy nke mbụ mere ka ndụ na-enweghị ọganihu na ndụ zuru oke dịkwuo mma site na njirimara nchekwa a na-achịkwa na ndị sonyere na kansa cervical na-adịgide adịgide, na-emegharị ugboro ugboro, ma ọ bụ na-eme ka metastatic. Data ndị a na-akwado ojiji nke cadonilimab gbakwunyere chemotherapy dị ka ọgwụgwọ mbụ dị irè na kansa cervical na-adịgide adịgide, na-emegharị ugboro ugboro, ma ọ bụ metastatic.

Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.

Nọmba ekwentị: 4008803716

Email：myimmnet@163.com